Clinical trial
Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in…
NCT00048308 · Alexion Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00048308 |
|---|---|
| Title | Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cardio-pulmonary Bypass, Coronary Artery Bypass Graft |
| Intervention type | Drug |
| Interventions | pexelizumab |
| Enrollment | 3,000 |
| Start date | Jan 1, 2002 |
| Primary completion | Mar 1, 2003 |
| First posted | Oct 31, 2002 |
| Last update posted | Feb 23, 2017 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: